Genzyme/Biomatrix
This article was originally published in The Gray Sheet
Executive Summary
Planned merger of Genzyme Tissue Repair, Genzyme Surgical Products and Biomatrix gains Federal Trade Commission anti-trust clearance, the companies announce June 26. Shareholder meetings are planned for the third quarter to finalize the deal. Initially anticipated to close in June, the merger has been delayed in order to respond to requests from the Securities and Exchange Commission regarding joint proxy statement